Answers are grounded in this paper and cite their sources.
Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by resistant Gram-positive pathogens. Here, we evaluated the in vitro activities of eravacycline and comparator antimicrobial agents against a recent global collection of frequently encountered clinical isolates of Gram-positive bacteria. The CLSI broth microdilution method was used to determine in vitro MIC data for isolates of Enterococcus spp.
No takes yet. Share an insight, caveat, or question.
Morrissey et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: